Bayer and BMS Win NICE Round On Stivarga And Opdivo
Bayer and Bristol-Myers Squibb have convinced the UK’s NICE to revisit its earlier recommendations and make their cancer treatments, Stivarga and Opdivo respectively, available for patients on the National Health Service.
You may also be interested in...
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.